Salcaprozate Sodium (SNAC) - Effective Oral Absorption Enhancer for APIs.

Salcaprozate Sodium (SNAC, CAS: 203787-91-1) is a pharmaceutical-grade absorption enhancer specifically designed to improve the oral bioavailability of peptide drugs and small molecules. With official approvals from both China CDE (F20220000072) and US FDA (037135), this high-purity excipient enables effective oral delivery of challenging APIs. Manufactured by Hefei TianRui Pharmaceutical under cGMP conditions, SNAC offers reliable quality and consistent performance for innovative formulation development.

Company Profile

• Founded: 2014

• Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology

• Facilities:

  • Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year

  • Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)

  • Ultra-low temperature cryogenic reactor (explosion-proof workshop included)

  • GMP workshop & clean room

• QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

• 

• 
• 
• 
  

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.